Please wait a minute...

Frontiers of Medicine

Front. Med.    2020, Vol. 14 Issue (2) : 117-125
Advances in COVID-19: the virus, the pathogenesis, and evidence-based control and therapeutic strategies
Guangbiao Zhou1(), Saijuan Chen2, Zhu Chen2()
1. State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
2. State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine (Shanghai), Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
Download: PDF(860 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Since the outbreak of the COVID-19 pandemic in early December 2019, 81 174 confirmed cases and 3242 deaths have been reported in China as of March 19, 2020. The Chinese people and government have contributed huge efforts to combat this disease, resulting in significant improvement of the situation, with 58 new cases (34 were imported cases) and 11 new deaths reported on March 19, 2020. However, as of March 19, 2020, the COVID-19 pandemic continues to develop in 167 countries/territories outside of China, and 128 665 confirmed cases and 5536 deaths have been reported, with 16 498 new cases and 817 new deaths occurring in last 24 hours. Therefore, the world should work together to fight against this pandemic. Here, we review the recent advances in COVID-19, including the insights in the virus, the responses of the host cells, the cytokine release syndrome, and the therapeutic approaches to inhibit the virus and alleviate the cytokine storm. By sharing knowledge and deepening our understanding of the virus and the disease pathogenesis, we believe that the community can efficiently develop effective vaccines and drugs, and the mankind will eventually win this battle against this pandemic.

Keywords COVID-19      SARS-CoV-2      pathogenesis      evidence-based medicine      control and therapeutic strategies     
Corresponding Authors: Guangbiao Zhou,Zhu Chen   
Just Accepted Date: 21 March 2020   Online First Date: 20 April 2020    Issue Date: 09 May 2020
 Cite this article:   
Guangbiao Zhou,Saijuan Chen,Zhu Chen. Advances in COVID-19: the virus, the pathogenesis, and evidence-based control and therapeutic strategies[J]. Front. Med., 2020, 14(2): 117-125.
E-mail this article
E-mail Alert
Articles by authors
Guangbiao Zhou
Saijuan Chen
Zhu Chen
Fig.1  The putative life cycle of SARS-CoV-2.
Fig.2  Cytokine storm and related symptoms of COVID-19.
Organs/systems Syndromes
General symptoms Fever, fatigue
Lung Tachypnea, hypoxia, pulmonary edema, respiratory failure
Blood Cytopenias, coagulopathy, febrile neutropenia, disseminated intravascular coagulation
Heart Tachycardia, hypotension, troponin elevation, arrhythmia, QT prolongation, stress, cardiomyopathy, acute heart failure
Liver Hepatomegaly, elevated liver enzymes, hypofibrinogeniemia, liver failure
Kidney Acute kidney injury, renal failure
Central nervous system Headaches, confusion, hallucinations, delirium, aphasia, paresis, seizures
Ileum Diarrhea
Musculoskeletal system Myalgia, arthralgia, rigor, rash, edema
Stomach Nausea, vomiting
Spleen Splenomegaly
Tab.1  Clinical features of CRS
Fig.3  SARS-CoV-2-induced injury and failure of the lungs, and therapeutic strategies against COVID-19. ARDS, acute respiratory distress syndrome.
1 R Yan, Y Zhang, Y Li, L Xia, Y Guo, Q Zhou. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. Science 2020 Mar 4. [Epub ahead of print] doi: 10.1126/science.abb2762
2 World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). 2020.
3 World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report — 59. March 19, 2020.
4 World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report — 37. February 26, 2020.
5 Y Zhang, D Cao. Wuhan to close its largest makeshift hospital. China Daily. March 7, 2020.
6 World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 — 11 March 2020. March 11, 2020.
7 S Kannan, P Shaik Syed Ali, A Sheeza, K Hemalatha. COVID-19 (novel coronavirus 2019) — recent trends. Eur Rev Med Pharmacol Sci 2020; 24(4): 2006–2011 pmid: 32141569
8 M Wang, R Cao, L Zhang, X Yang, J Liu, M Xu, Z Shi, Z Hu, W Zhong, G Xiao. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30(3): 269–271 pmid: 32020029
9 X Tang, C Wu, X Li, Y Song, X Yao, X Wu, Y Duan, H Zhang, Y Wang, Z Qian, J Cui, J Lu. On the origin and continuing evolution of SARS-CoV-2. Natl Sci Rev 2020 Mar 3. [Epub ahead of print] doi:10.1093/nsr/nwaa036
10 OA Maclean, R Orton, J Singer, DL Robertson. Response to “On the origin and continuing evolution of SARS-CoV-2”. 2020. (accessed March 7, 2020)
11 L Zhang, J-R Yang, Z Zhang, Z Lin. Genomic variations of SARS-CoV-2 suggest multiple outbreak sources of transmission. medRxiv 2020; doi: 10.1101/2020.02.25.20027953
12 C Ceraolo, FM Giorgi. Genomic variance of the 2019-nCoV coronavirus. J Med Virol 2020; 92: 522–528
13 A Wu, P Niu, L Wang, H Zhou, X Zhao, W Wang, et al.. Mutations, recombination and insertion in the evolution of 2019-nCoV. bioRxiv 2020; doi: 10.1101/2020.02.29.971101
14 WB Yu, GD Tang, L Zhang, RT Corlett. Decoding evolution and transmissions of novel pneumonia coronavirus using the whole genomic data. ChinaXiv 2020. (accessed March 19, 2020)
15 KG Andersen, A Rambaut, WI Lipkin, EC Holmes, RF Garry. The proximal origin of SARS-CoV-2. Nat Med 2020. [Epub ahead of print] doi: 10.1038/s41591-020-0820-9
16 H Liu, C Wu, Y Yang, Y Liu, P Zhang, Y Wang, Q Wang, et al.. Furin, a potential therapeutic target for COVID-19. ChinaXiv 2020. (accessed March 19, 2020)
17 M Hoffmann, H Kleine-Weber, S Schroeder, N Krüger, T Herrler, S Erichsen, TS Schiergens, G Herrler, NH Wu, A Nitsche, MA Müller, C Drosten, S Pöhlmann. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020 Mar 4. [Epub ahead of print] doi: 10.1016/j.cell.2020.02.052 pmid: 32142651
18 X Zou, K Chen, J Zou, P Han, J Hao, Z Han. The single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med 2020 Mar 12. [Epub ahead of print] doi: 10.1007/s11684-020-0754-0
19 L Du, Y He, Y Zhou, S Liu, BJ Zheng, S Jiang. The spike protein of SARS-CoV—a target for vaccine and therapeutic development. Nat Rev Microbiol 2009; 7(3): 226–236 pmid: 19198616
20 R Lu, X Zhao, J Li, P Niu, B Yang, H Wu, W Wang, H Song, B Huang, N Zhu, Y Bi, X Ma, F Zhan, L Wang, T Hu, H Zhou, Z Hu, W Zhou, L Zhao, J Chen, Y Meng, J Wang, Y Lin, J Yuan, Z Xie, J Ma, WJ Liu, D Wang, W Xu, EC Holmes, GF Gao, G Wu, W Chen, W Shi, W Tan. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395(10224): 565–574 pmid: 32007145
21 N Chen, M Zhou, X Dong, J Qu, F Gong, Y Han, Y Qiu, J Wang, Y Liu, Y Wei, J Xia, T Yu, X Zhang, L Zhang. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223): 507–513 pmid: 32007143
22 D Wang, B Hu, C Hu, F Zhu, X Liu, J Zhang, B Wang, H Xiang, Z Cheng, Y Xiong, Y Zhao, Y Li, X Wang, Z Peng. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323(11): 1061 pmid: 32031570
23 WJ Guan, ZY Ni, Y Hu, WH Liang, CQ Ou, JX He, L Liu, H Shan, CL Lei, DSC Hui, B Du, LJ Li, G Zeng, KY Yuen, RC Chen, CL Tang, T Wang, PY Chen, J Xiang, SY Li, JL Wang, ZJ Liang, YX Peng, L Wei, Y Liu, YH Hu, P Peng, JM Wang, JY Liu, Z Chen, G Li, ZJ Zheng, SQ Qiu, J Luo, CJ Ye, SY Zhu, NS Zhong; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020 Feb 28. [Epub ahead of print] doi: 10.1056/NEJMoa2002032 pmid: 32109013
24 J Liu, S Li, J Liu, B Liang, X Wang, H Wang, et al.. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. medRxiv 2020; doi: 10.1101/2020.02.16.20023671
25 B Diao, C Wang, Y Tan, X Chen, Y Liu, L Ning, et al.. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). medRxiv 2020; doi: 10.1101/2020.02.18.20024364
26 Z Zhang, X Li, W Zhang, ZL Shi, Z Zheng, T Wang. Clinical features and treatment of 2019-nCov pneumonia patients in Wuhan: report of a couple cases. Virol Sin 2020 Feb 7. [Epub ahead of print] doi: 10.1007/s12250-020-00203-8 pmid: 32034637
27 W Wang, J He, P Lie, L Huang, S Wu, Y Lin, et al.. The definition and risks of cytokine release syndrome-like in 11 COVID-19-infected pneumonia critically ill patients: disease characteristics and retrospective analysis. medRxiv 2020; doi: 10.1101/2020.02.26. 20026989
28 A Nazinitsky, KS Rosenthal. Cytokine storms: systemic disasters of infectious diseases. Infect Dis Clin Pract 2010; 18(3): 188–192
29 L Chatenoud, C Ferran, A Reuter, C Legendre, Y Gevaert, H Kreis, P Franchimont, JF Bach. Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-γ [corrected]. N Engl J Med 1989; 320(21): 1420–1421 pmid: 2785642
30 EM Behrens. Cytokines in cytokine storm syndrome. In: Cron RQ, Behrens EM. Cytokine Storm Syndrome. Cham: Springer International Publishing, 2019. 197–207
31 T Okabayashi, H Kariwa, S Yokota, S Iki, T Indoh, N Yokosawa, I Takashima, H Tsutsumi, N Fujii. Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections. J Med Virol 2006; 78(4): 417–424 pmid: 16482545
32 JR Teijaro, KB Walsh, S Cahalan, DM Fremgen, E Roberts, F Scott, E Martinborough, R Peach, MB Oldstone, H Rosen. Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell 2011; 146(6): 980–991 pmid: 21925319
33 R Channappanavar, S Perlman. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol 2017; 39(5): 529–539 pmid: 28466096
34 T Liu, J Zhang, Y Yang, H Ma, Z Li, J Zhang, et al.. The potential role of IL-6 in monitoring severe case of coronavirus disease 2019. medRxiv 2020; doi: 10.1101/2020.03.01.20029769
35 L Yu, Y Tong, G Shen, A Fu, Y Lai, X Zhou, et al.. Immunodepletion with hypoxemia: a potential high risk subtype of coronavirus disease 2019. medRxiv 2020; doi: 10.1101/2020. 03.03.20030650
36 Z Xu, L Shi, Y Wang, J Zhang, L Huang, C Zhang, S Liu, P Zhao, H Liu, L Zhu, Y Tai, C Bai, T Gao, J Song, P Xia, J Dong, J Zhao, FS Wang. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020 Feb 18. [Epub ahead of print] doi: 10.1016/S2213-2600(20)30076-X pmid: 32085846
37 Y Zhou, B Fu, X Zheng, D Wang, C Zhao, Y Qi, et al.. Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus. bioRxiv 2020; doi: 10.1101/2020.02.12.945576
38 KJ Huang, IJ Su, M Theron, YC Wu, SK Lai, CC Liu, HY Lei. An interferon-g-related cytokine storm in SARS patients. J Med Virol 2005; 75(2): 185–194 pmid: 15602737
39 W Luo, H Yu, J Gou, X Li, Y Sun, J Li, L Liu. Clinical pathology of critical patient with novel coronavirus pneumonia (COVID-19). Preprints 2020; 2020020407 (accessed March 19, 2020)
40 P Zhou, XL Yang, XG Wang, B Hu, L Zhang, W Zhang, HR Si, Y Zhu, B Li, CL Huang, HD Chen, J Chen, Y Luo, H Guo, RD Jiang, MQ Liu, Y Chen, XR Shen, X Wang, XS Zheng, K Zhao, QJ Chen, F Deng, LL Liu, B Yan, FX Zhan, YY Wang, GF Xiao, ZL Shi. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579(7798): 270–273 pmid: 32015507
41 C Anastassopoulou, L Russo, A Tsakris, C. Siettos Data-based analysis, modelling and forecasting of the novel coronavirus (2019-nCoV) outbreak. medRxiv 2020; doi: 10.1101/2020.02.11. 20022186
42 Q Li, X Guan, P Wu, X Wang, L Zhou, Y Tong, R Ren, KSM Leung, EHY Lau, JY Wong, X Xing, N Xiang, Y Wu, C Li, Q Chen, D Li, T Liu, J Zhao, M Liu, W Tu, C Chen, L Jin, R Yang, Q Wang, S Zhou, R Wang, H Liu, Y Luo, Y Liu, G Shao, H Li, Z Tao, Y Yang, Z Deng, B Liu, Z Ma, Y Zhang, G Shi, TTY Lam, JTK Wu, GF Gao, BJ Cowling, B Yang, GM Leung, Z Feng. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020 Jan 29. [Epub ahead of print] doi: 10.1056/NEJMoa2001316 pmid: 31995857
43 Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Chin J Epidemiol (Zhonghua Liu Xing Bing Xue Za Zhi) 2020; 41(2): 145–151 (in Chinese)
pmid: 32064853
44 K Duan, B Liu, C Li, H Zhang, T Yu, J Qu, et al.. The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study. Proc Natl Acad Sci USA 2020; doi: 10.1073/pnas.2004168117 pmid: 32113510
45 L Chen, J Xiong, L Bao, Y Shi. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis 2020 Feb 27. [Epub ahead of print] doi: 10.1016/S1473-3099(20)30141-9 pmid: 32113510
46 ML Holshue, C DeBolt, S Lindquist, KH Lofy, J Wiesman, H Bruce, C Spitters, K Ericson, S Wilkerson, A Tural, G Diaz, A Cohn, L Fox, A Patel, SI Gerber, L Kim, S Tong, X Lu, S Lindstrom, MA Pallansch, WC Weldon, HM Biggs, TM Uyeki, SK Pillai; Washington State 2019-nCoV Case Investigation Team. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020; 382(10): 929–936 pmid: 32004427
47 N Zhu, D Zhang, W Wang, X Li, B Yang, J Song, X Zhao, B Huang, W Shi, R Lu, P Niu, F Zhan, X Ma, D Wang, W Xu, G Wu, GF Gao, W Tan; China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382(8): 727–733 pmid: 31978945
48 V Staedtke, RY Bai, K Kim, M Darvas, ML Davila, GJ Riggins, PB Rothman, N Papadopoulos, KW Kinzler, B Vogelstein, S Zhou. Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. Nature 2018; 564(7735): 273–277 pmid: 30542164
49 NR London, W Zhu, FA Bozza, MCP Smith, DM Greif, LK Sorensen, et al.. Targeting Robo4-dependent Slit signaling to survive the cytokine storm in sepsis and influenza. Sci Transl Med 2010; 2(23): 23ra19
50 X Liu, Z Li, S Liu, Z Chen, Z Zhao, YY Huang, et al.. Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction. medRxiv 2020; doi: 10.1101/2020.02.27.20027557
51 S Pfaender, KB Mar, E Michailidis, A Kratzel, D Hirt, P V’kovski, et al.. LY6E impairs coronavirus fusion and confers immune control of viral disease. bioRxiv 2020; doi: 10.1101/2020.03.05.979260
52 C Wu, Y Liu, Y Yang, P Zhang, W Zhong, Y Wang, Q Wang, Y Xu, M Li, X Li, M Zheng, L Chen, H Li. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B 2020 Feb 27. [Epub ahead of print] doi:10.1016/j.apsb.2020.02.008
53 A Rimanshee, D Amit, P Vishal, K Mukesh. Potential inhibitors against papain-like protease of novel coronavirus (SARS-CoV-2) from FDA approved drugs. ChemRxiv 2020; doi: 10.26434/chemrxiv.11860011.v2
54 ul Tahir M Qamar, S Alqahtani, M Alamri, L Chen. Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants. Preprints 2020; 2020020193 (accessed March 19, 2020)
55 B Cao, Y Wang, D Wen, W Liu, J Wang, G Fan, L Ruan, B Song, Y Cai, M Wei, X Li, J Xia, N Chen, J Xiang, T Yu, T Bai, X Xie, L Zhang, C Li, Y Yuan, H Chen, H Li, H Huang, S Tu, F Gong, Y Liu, Y Wei, C Dong, F Zhou, X Gu, J Xu, Z Liu, Y Zhang, H Li, L Shang, K Wang, K Li, X Zhou, X Dong, Z Qu, S Lu, X Hu, S Ruan, S Luo, J Wu, L Peng, F Cheng, L Pan, J Zou, C Jia, J Wang, X Liu, S Wang, X Wu, Q Ge, J He, H Zhan, F Qiu, L Guo, C Huang, T Jaki, FG Hayden, PW Horby, D Zhang, C Wang. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med 2020 Mar 18. [Epub ahead of print] doi: 10.1056/NEJMoa2001282 pmid: 32187464
Related articles from Frontiers Journals
[1] Tianhua Xu, Zitong Sheng, Li Yao. Obesity-related glomerulopathy: pathogenesis, pathologic, clinical characteristics and treatment[J]. Front. Med., 2017, 11(3): 340-348.
[2] Sicheng Wang, He Yu, Jianping Liu, Baoyan Liu. Exploring the methodology and application of clinical pathway in evidence-based Chinese medicine[J]. Front Med, 2011, 5(2): 157-162.
[3] Baoyan Liu, Yanhong Zhang, Jingqing Hu, Liyun He, Xuezhong Zhou. Thinking and practice of accelerating transformation of traditional Chinese medicine from experience medicine to evidence-based medicine[J]. Front Med, 2011, 5(2): 163-170.
[4] Qi-De LIN, Li-Hua QIU. Pathogenesis, diagnosis, and treatment of recurrent spontaneous abortion with immune type[J]. Front Med Chin, 2010, 4(3): 275-279.
[5] Kelvin Kai-Wang TO FRCPath, Iris Wai-Sum LI FRCP, Ivan Fan-Ngai HUNG FRCP, Vincent Chi-Chung CHENG FRCPath, Kwok-Yung YUEN MD, . Pathogenesis of pandemic H1N1 2009 influenza virus infection and the implication on management[J]. Front. Med., 2010, 4(2): 147-156.
[6] Lan-Juan LI MD, . Review of hand, foot and mouth disease[J]. Front. Med., 2010, 4(2): 139-146.
Full text